• Home
• Responsibility
• CR Review 2006
• Managing CR

Managing CR

Our Corporate Responsibility Statement and Principles define our approach to CR and provide guidance for employees on the standards we are committed to.

We have a Corporate Responsibility Committee of non-executive board directors which provides high-level guidance on our approach to CR. The CEO and members of the corporate executive team are actively inovlved in CR and participate in the CRC meetings.

Management of significant business risks, including reputational and CR risks, is coordinated by the Risk and Oversight Compliance Council (ROCC).

Duncan Learmouth, Senior Vice President Corporate Communications and Community Partnerships, and Rupert Bondy, General Counsel, are our executive committee members with responsibility for CR and environment.

We believe that day-to-day management of CR is done most effectively within our business operations, where experts on all our CR issues work. We also have a small CR team that co-ordinates policy development, reporting and communication.

Assurance
The environment, health and safety sections of our report are externally verified by SCS UK Limited.

Stakeholder engagement
We believe it is important to engage with stakeholders. This helps us to identify material CR issues for our business, understand stakeholder views and expectations and build trust with key audiences. We also discuss our work and learn from stakeholders’ expertise. GSK interacts with a wide range of stakeholders including:

• Patients
• Doctors
• Governments and regulators
• Public and private health providers
• NGOs
• Multilateral organisations
• Employees
• Investors
• Local communities
• Suppliers
• The scientific and academic community

Most of this discussion takes place in the normal course of business. For example our scientists meet regularly with academics and researchers.

We are developing a more structured approach to stakeholder engagement to ensure we target our resources and integrate stakeholder feedback into our decision-making processes. We will focus in particular on stakeholders relevant to healthcare in the developing world.

GSK is included in the FTSE4Good Index and Dow Jones Sustainability Index.

Government and external affairs
GSK’s External Affairs teams monitor changes and proposed reforms to legislation and meet regularly with government officials to explain our views on a range of public policy issues. Lobbying on issues affecting the pharmaceutical industry is sometimes conducted through trade associations. We may also hire professional lobbyists to support this work.

Our public policy work is governed by our External Affairs Code of Conduct, and backed up by factual research and analysis.

We have additional policies governing our interactions with patient groups. We list all European patient groups receiving funding from GSK and the amount given to each group in the background section of our website.

Back to top